Przeglądanie według Temat "vaccine"

Aktualnie wyświetlane 1 - 2 z 2

Evaluation of manufacturing specification of antifungal vaccines
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2016) Nedosekov, Vitaly; Martynyuk, Oleksandr; Stetsiura, Lesya
In this article are presented the algorithm of manufacture vaccines against dermatomycoses carnivores based on original research stages manufacture of vaccines. Shown biotechnological aspects of selection isolates the study of immunological properties of strains of dermatophytes, ways to optimize cultivation conditions and methods of working hours of raw material. The basic stages of biotechnology development inactivated vaccines against dermatomycoses dogs and cats, for example vaccines „Funhikanifel” inactivated associated against dermatomycoses dogs and cats. The authors have developed technological regulation manufacture of vaccines against dermatomycoses, allowing for high immunogenic properties and the harmlessness for immunization of dogs, cats and laboratory animals. In the article focuses on the selection of isolates of dermatophytes on morphological features that will continue to be crucial in the production of highly effective vaccine. Experimentally, the possibility of a vaccine using domestic raw materials, which has priority from the standpoint of national biosafety.
Serum levels of anti-corona virus specific -IgG and -IgM antibodies in COVID-19 patients at admission and at discharge
(Wydawnictwo Uniwersytetu Rzeszowskiego, 2021) Ganiyu, Arinola
Introduction. Clear understanding of duration of antibody based protective immunity following natural infection with SARSCoV- 2 will give idea about the efficacy of proposed prophylactic vaccines against SARS-CoV-2, establishment of herd immunity and use of convalescent plasma. Aim. This study clarified the kinetics and magnitude of the initial antibody response against SARS-CoV-2 in a cohort of symptomatic COVID-19 patients from Ibadan, Nigeria. Material and methods. This study quantified immunoglobulin M (IgM) and G (IgG) antibodies recognizing the SARS-CoV-2 Spike (S) protein in 35 symptomatic COVID-19 patients at admission and at discharge using ELISA. Results. CovIgG was positive in none (0)% and 20% of COVID-19 patients at admission and at discharge respectively while CovIgM was positive in 54% and 69% of COVID-19 patients at admission and at discharged respectively. The level of CovIgG was significantly higher in COVID-19 patients at discharge compared with the level at admission while the level of CovIgM was insignificantly reduced in COVID-19 patients at discharge compared with the level at admission. Conclusion. The data indicates increased anti-SARS-COV-2 IgG Spike antibody in symptomatic COVID-19 at discharge, thus providing basis for antibody-based therapies to treat COVID-19 patients.